Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $23.00 Consensus Target Price from Analysts

Posted by Francis Steltz on Jun 4th, 2026

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $23.00.

A number of equities research analysts have recently issued reports on AMLX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Friday, May 8th. Stifel Nicolaus started coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday, March 3rd. They set a “buy” rating and a $21.00 target price for the company. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Bank of America upped their target price on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Finally, Mizuho upped their target price on shares of Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th.

View Our Latest Analysis on AMLX

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Hedge funds have recently modified their holdings of the company. KBC Group NV purchased a new stake in shares of Amylyx Pharmaceuticals in the first quarter valued at about $26,000. Meeder Asset Management Inc. purchased a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $25,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Amylyx Pharmaceuticals in the third quarter valued at about $48,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Amylyx Pharmaceuticals by 954.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after purchasing an additional 3,493 shares during the period. Finally, California State Teachers Retirement System purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at about $28,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Down 0.7%

Amylyx Pharmaceuticals stock opened at $13.20 on Friday. Amylyx Pharmaceuticals has a 52-week low of $4.76 and a 52-week high of $18.60. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -8.80 and a beta of -0.16. The company has a fifty day simple moving average of $15.14 and a 200-day simple moving average of $14.28.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). On average, research analysts anticipate that Amylyx Pharmaceuticals will post -1.4 EPS for the current fiscal year.

About Amylyx Pharmaceuticals

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.